We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 13, 2021

Exenatide and Dapagliflozin Alone or in Combination and Kidney Function in Obese Patients With T2D

Diabetes, Obesity & Metabolism

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Effect of Exenatide Twice Daily and Dapagliflozin Alone and in Combination on Markers of Kidney Function in Obese Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Controlled Clinical Trial
Diabetes Obes Metab 2021 Apr 28;[EPub Ahead of Print], CC van Ruiten, AB van der Aart-van der Beek, RG IJzerman, M Nieuwdorp, K Hoogenberg, DH van Raalte, HJL Heerspink

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading